Qirui Medicine (Hope Medicine, referred to as "Heqi
Rui") is a company dedicated to source innovation and science
1-driven innovative drug research and development company with its headquarters in China
Located in Nanjing, and has R&D bases and offices in Shanghai and Beijing at the same time
Office. The establishment of the company is based on the Future Institute of Technology of Peking University.
Professor Ruiping and his team's deep understanding in the field of translational medicine research
And decades of research results. Heqirui is based on outstanding scientific research
Based on the goal of improving the quality of life, it targets threats to human health.
Common diseases and major diseases, committed to research, development and commercialization.
Innovative medicine.
and
Recently, Heqirui announced the appointment of members of the company's board of directors and the original
President and head of Clinical research and Development Henri, Nico, Duz (Henri
Nico Doods) became CEO. He will promote and practice public
The company's strategic goals ensure more clinical milestones in the future
Achieve, and lead the company towards "becoming science-driven and focusing on the future".
A global biopharmaceutical innovation R&D company that follows science and technology and pioneering new drugs
Industry"keeps moving forward.
Before joining Heqirui, Duz worked for Bollinger Langer Henkel.
Senior vice president, with more than 30 years of experience in pharmaceutical research and development, covering the heart
In the fields of blood vessels, nerves, and respiration, he has participated in more than 15 projects.
R&D projects that have entered the clinical stage.
Duz said: "Heqirui has an excellent team and a strong
Global intellectual property rights, and also has world-class clinical R&D partners
Partner and expert network support. I am very honored to be the head of the company
As chief executive officer, I will work hard to accelerate the company's current clinical research.
Research the progress of the project, focus on research and development, and formulate the company's future
Various strategic development plans, in order to realize Heqirui's becoming a global
Biopharmaceutical companies, for the benefit of more patients' vision, make the most
Great effort. "
Xiao Ruiping, chairman and founder of Heqirui, said: "As
Senior scientists and top experts in the global pharmaceutical industry, Duz does not
Only in the field of scientific research and development, it has achieved great results, and what is even more valuable is,
He has excellent business development and management experience in the industry. Made
As the founder of the company, I am very grateful to Duz for his letter to the company and me.
Ren, be able to accept such a heavy responsibility. At the same time, Duz serves as the chief
The executive officer is an important chapter in the company's history and symbolizes the company's leadership.
The guidance level has reached a new strategic height. Hope to be led by Duz
Under the management of the company, the company can smoothly move towards more research and development milestones.
God. "
The CEO will lead all employees of the company to continue to this goal
Move forward firmly. "Heqirui co-founder, president and Chief operating officer
The official class is telling the truth.
In the first half of 2021, Heqirui announced the completion of a scale of 56 million
Series B financing in U.S. dollars. This round of financing was funded by Qiming Venture Capital and Yuanyi Investment
Jointly led the investment, Honghui Capital and Innovation Workshop followed, and the old shareholder Bi Xin
The capital continues to be blessed, and Haoyue Capital serves as the exclusive financial adviser. This
The round of investment will be for the upcoming international multi-center clinical trial of Heqirui
The second phase of MRCT research and product line construction provide strong
support. IEE
"Duz's appointment has further strengthened He Qirui's leadership,
It will also bring a new atmosphere to the team. Heqirui is based on the source of China's innovation
New, the goal is to become a global biopharmaceutical company, and Duz serves as
Editor of this article: Li Qian, contact email:
157720740@qq.com
The 9th issue of 2021 will be processed 17
for highest quality:
7332.png (1500×1975) (zupimages.net)